National Institute for Health and Care Excellence (NICE) has suggested a new treatment option for people managing obesity and non-diabetic hyperglycaemia alongside a reduced-calorie diet and increased physical activity.
NICE has recommended Liraglutide (aka Saxenda and made by Novo Nordisk) to adults with non-diabetic hyperglycaemia who have a body mass index (BMI) of at least 35 kg per m2 and have a high risk of cardiovascular disease because of risk factors such as high blood pressure or high cholesterol levels.
The pre-filled injection pens will be prescribed in secondary care, by a specialist multidisciplinary tier 3 weight management service. People who are referred to a tier 3 service will normally have been offered weight management interventions in a local, intensive lifestyle-change programme (such as the NHS diabetes prevention programme) first.
Maximum two years
As per the draft guidance, treatment with liraglutide should be discontinued if at least 5 per cent body weight has not been lost after 12 weeks on the full dose. Treatment for all patients will stop after two years.
Earlier, NICE had not been able to recommend the treatment because the cost-effectiveness estimate was highly uncertain and potentially much higher than NICE considers a cost-effective use of NHS resources. However, the company has now agreed a confidential discount with NHS England and NHS Improvement, which reduces this uncertainty.
According to Meindert Boysen, deputy chief executive and director of the Centre for Health Technology Evaluation at NICE, “There is a real need for more treatment options for obese adults with non-diabetic hyperglycaemia who have a high risk of experiencing the adverse consequences of obesity, such as type 2 diabetes and cardiovascular disease.
He said their independent committee was presented with clinical evidence which showed that people lose more weight with liraglutide plus lifestyle measures than with lifestyle measures alone.
Liraglutide may also delay the development of type 2 diabetes and cardiovascular disease and this is the main benefit of treatment.
The guidance covers the management of obesity and non-diabetic hyperglycaemia in a specialist weight management (tier 3) service.
(With inputs from The OnLook News Research Bureau)